Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 4,767 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Branch II Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: acupuncture therapy, questionnaire administration, management of therapy complications; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Colorectal Cancer
Interventions: annual screening, fecal occult blood test, screening colonoscopy, standard follow-up care; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 40 Years to 69 Years
Enrollment: 4,952 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2026
U.S. locations: 4
States / cities: Shreveport, Louisiana • Minneapolis, Minnesota • New York, New York + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery; Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: Phoenix, Arizona • Duarte, California • Orange, California + 25 more

Conditions: Breast Neoplasms
Interventions: Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 2
States / cities: West Hollywood, California • Boston, Massachusetts

Conditions: Malignant Lung Neoplasm
Interventions: Standard Follow-Up Care, Caregiver-Related Intervention or Procedure, Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Duarte, California

Conditions: Gastroparesis
Interventions: Gastric Electrical Stimulation (GES) System; Device
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: HER2 Negative Breast Cancer
Interventions: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: > 15% risk of + LN; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions: mometasone furoate, placebo; Drug · Other
Lead sponsor: North Central Cancer Treatment Group; Network
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 189
States / cities: Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Afatinib, Paclitaxel, Carboplatin, Cisplatin, Intensity Modulated Radiation Therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Nashville, Tennessee

Conditions: Graft Versus Host Disease
Interventions: Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Abemaciclib, Biopsy, Bone Scan, Echocardiography, Exemestane, Gemcitabine, Letrozole, Multigated Acquisition Scan, Osimertinib, Pemetrexed, Survey Administration, Tamoxifen, Biospecimen Collection; Drug · Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 148
States / cities: Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more

Conditions: Colon Cancer, Peripheral Neuropathy
Interventions: Cryotherapy Gloves; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Acquired Immunodeficiency Syndrome, HIV
Interventions: Provider Visit Incentive (PVI), Incentive Choice (IC); Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
Interventions: Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride; Biological · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 11
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions: Pembrolizumab, Olaparib, Radiation; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Prostate Cancer Metastatic, Prostate Cancer, CRPC
Interventions: Enhertu; Drug
Lead sponsor: Washington D.C. Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Renal Cell Carcinoma
Interventions: Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250, Positron emission tomography/computed tomography, Protein expression analysis, Immunohistochemistry; Drug · Genetic · Other + 1 more
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions: alrizomadlin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignant Central Nervous System Neoplasm
Interventions: Anhydrous Enol-oxaloacetate, Best Practice, Biospecimen Collection, Magnetic Resonance Spectroscopic Imaging, Questionnaire Administration; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease
Interventions: Surgery; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Clofarabine, Fludarabine, Hematopoietic Cell Transplantation, Total-Body Irradiation, Treosulfan, Echocardiography Test, Multigated Acquisition Scan, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection; Drug · Procedure · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Video-Assisted Intervention in Improving Recovery in Patients With Cancer Undergoing Lung Surgery and Caregivers

Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Cryotherapy & Oxaliplatin

A Commitment Device for Medication Adherence Among HIV Patients

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Castrate Resistant Prostate Cancer Enhertu Therapy

Brivanib Metastatic Renal Cell Carcinoma

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia